Search Results

CNNC Changchun Nuclear Medicine Base Obtains Production License

On August 28, the Jilin Provincial Drug Administration approved and issued the "Radiopharmaceutical Production License" to Changchun Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as "Changchun Hi-Tech"), a subsidiary of Atomic Hi-Tech under China Isotope & Radiation Corporation (CIRC). The acquisition of this license marks that Changchun Hi-Tech is now fully qualified for the production of technetium-labeled drugs. Radiopharmaceuticals are characterized by short half-lives, high transportation requirements, and strict time sensitivity. Long-distance transportation not only increases transportation and time costs but also poses greater challenges to the stability and timeliness of clinical medication. With the production qualification, Changchun Hi-Tech will be able to complete the production and distribution of technetium-labeled drugs locally in Jilin Province, which will help improve the clinical use of nuclear medicine in the Northeast region...

2026-08-29

Thor Medical Advances AlphaOne Commercial Production in H1, Completes First Customer Deliveries of Lead-212 Isotope

Thor Medical ASA, a supplier of high-purity isotopes to the radiopharmaceutical industry, announced its H1 2026 results on August 28. The company stated that its AlphaOne facility has completed mechanical construction on time and on budget and has entered commercial production, marking the start of a new phase focused on scaling output, increasing customer deliveries, and growing revenue. Thor Medical CEO Jasper Kurth said that with the completion of the first customer product deliveries from AlphaOne, the company has established a solid commercial foundation in a rapidly growing market, and the next step is to advance the execution plan around capacity expansion, customer deliveries, and revenue growth to support the development of next-generation precision cancer therapies...

2026-08-28

Russian Thorium-Based Radiopharmaceuticals Expected Within 1-2 Years

On August 27, Igor Korobko, Professor of the Russian Academy of Sciences and Director of the Department of Medical and Scientific Development in Healthcare of the Russian Ministry of Health, stated at the Technoprom Forum held in Novosibirsk that thorium-based drugs for precision radionuclide therapy of tumors are expected to become available in Russia within the next 1 to 2 years. Korobko noted that tumor treatment still requires support from more available isotopes. For example, when patients develop resistance to actinium-related therapies, clinical practice necessitates the use of different isotopes for treatment. He stated that Russia is advancing the development of related therapies domestically and expects to have thorium-based drugs within the next year or two. Currently, actinium-225 is considered one of the more promising radionuclides...

2026-08-28

Russia Plans to Complete Development of First Domestic Proton Beam Therapy Cyclotron by 2027

Russian scientists plan to complete the development of the country's first domestically produced proton beam therapy cyclotron by 2027, with commissioning to begin in the same year. This progress was announced by Sergey Gertzog, CEO of the Russian National Institute of Electronics and Atomic Energy (NIIEFA), at the recent Technoprom forum held in Novosibirsk. A proton beam therapy cyclotron is a type of charged particle accelerator that uses magnetic and electric fields to accelerate protons to high-energy states, reaching speeds of one-half to two-thirds the speed of light. The accelerated proton beam can target cancerous tumor areas with relative precision for oncological treatment. According to the schedule outlined in Gertzog's report...

2026-08-28

Russia Advances Radiopharmaceutical Development, Plans to Expand into Diagnostics and Treatment of Heart Disease and Other Conditions

Rosatom is developing radiopharmaceuticals for the diagnosis and treatment of neurodegenerative diseases, heart disease, and rheumatic conditions, further expanding the application of radionuclide technology in medicine. During the 13th International Technology Development Forum Technoprom-2026 held in Novosibirsk, Sergei Surov, Director of the Department of Radionuclide Products and Nuclear Medicine at Rosatom's Science Division, stated that the company is advancing the development of these drugs. Radiopharmaceuticals typically contain radioactive isotopes, i.e., radionuclides, and are currently used in medicine primarily for the diagnosis and treatment of various cancers. Surov noted that the new development directions mean...

2026-08-28

Russia and Egypt Plan to Cooperate on Construction of Nuclear Medicine Center and Radiopharmaceutical Plant

Alexey Likhachev, CEO of Rosatom, recently stated that Russia and Egypt are expanding cooperation in non-energy nuclear technologies, with one of Egypt's key priorities being the construction of a high-performance nuclear medicine center based on a research reactor. According to reports, the project will adopt a comprehensive approach, including a radiopharmaceutical production plant, isotope production facilities, and modern diagnostic systems based on PET and SPECT technologies. Some diagnostic systems will use Russian equipment. Once completed, the project is expected to conduct up to 30,000 diagnostic examinations annually and provide treatment services for 400 patients. Construction of the medical facility is expected to begin as early as 2027...

2026-08-28

Bristol Myers Squibb to Invest $173 Million in New Radiopharmaceutical Plant in Indiana, USA

Bristol Myers Squibb's RayzeBio will build a new radiopharmaceutical production facility in Whitestown, Indiana, USA, with an investment of $173 million. The project will be located at the Anson Industrial Park in Boone County, with construction planned to begin this year, complementing RayzeBio's existing operational radiopharmaceutical plant in Indianapolis. According to information released by the state of Indiana, the new facility will cover approximately 225,000 square feet. Bristol Myers Squibb expects the two production sites to add 100 new positions by the end of 2029, with annual salaries for new positions expected to exceed $130,000. Bristol Myers Squibb acquired San Diego-based RayzeBio in 2023 for $4.1 billion...

2026-08-28

Huzhou, Zhejiang Launches Phase I "Drug-Device Combination" Clinical Trial for the Province's First BNCT System

Recently, the Boron Neutron Tumor Treatment Center at Huzhou Hospital Affiliated to Zhejiang University School of Medicine has drawn attention with the introduction of the province's first Boron Neutron Capture Therapy (BNCT) system. Previously, the system had already initiated a Phase I BNCT drug-device combination clinical trial. According to the system developer, Huapeng Neutron Technology (Hangzhou) Co., Ltd., BNCT is a radiotherapy technique combining drugs and devices, with its core lying in the coordinated use of boron-containing drugs and neutron irradiation. After entering the human body, the boron-containing drug can be absorbed by tumor cells; subsequent neutron beam irradiation triggers a localized reaction to achieve targeted radiotherapy against tumor cells. Unlike conventional radiotherapy, which typically employs fractionated irradiation over a longer treatment course, BNCT emphasizes selective targeting of tumor cells, aiming to reduce damage to surrounding healthy tissues and lower radiotherapy-related side effects such as hair loss and immunosuppression.

2026-08-27

Moffitt Cancer Center in the U.S. Launches $600 Million Radiopharmaceutical Program

Moffitt Cancer Center in Tampa, Florida, recently announced the launch of a new radiopharmaceutical program, planning to accelerate radiopharmaceutical research, development, and clinical translation through a total infrastructure investment of $600 million. The program will be advanced at the Speros campus of Moffitt Cancer Center in Pasco County, Florida. The campus spans 775 acres, and the related investment will support the development of radiopharmaceutical research and development capabilities, including the construction of new radiochemistry laboratories within the Moffitt Discovery and Innovation Center, which opens this fall. The innovation center has a building area of approximately 255,000 square feet. The program funding will also support the planned comprehensive theranostics center...

2026-08-27

Department of Nuclear Medicine at the Affiliated Hospital of Southwest Medical University Completes Its First PET/CT-Guided Interventional Puncture Procedure

From August 21 to 22, Professor Sun Long from the PET Center of the First Affiliated Hospital of Xiamen University was invited to the Department of Nuclear Medicine at the Affiliated Hospital of Southwest Medical University for academic exchange, and on the following day provided on-site guidance for the hospital's first PET/CT-guided interventional puncture procedure. The successful completion of this procedure marks a new clinical practice milestone for the department in the field of interventional nuclear medicine. On August 21, Professor Sun Long delivered a special lecture titled "Exploration of Clinical Integrated Application of Diagnostic Nuclear Medicine and Interventional Nuclear Medicine Based on the PET Platform," focusing on how the PET platform extends from disease diagnosis and precise localization to interventional diagnosis and treatment. Drawing on clinical practice and typical cases, he introduced the application of interventional nuclear medicine in lesion...

2026-08-27

Lanzhou Taiji Completes Key Commissioning of First Domestic Multi-Ion Therapy Device HiTS400

The first domestically produced multi-ion therapy device HiTS400, independently developed by Lanzhou Taiji and installed at Shandong Cancer Hospital, recently completed phased joint commissioning. After one week of operational testing, all beam parameters of the device met or exceeded contractual requirements, laying the foundation for subsequent clinical registration work. According to reports, HiTS400 is a medical ion accelerator independently developed by Lanzhou Taiji with full intellectual property rights. It can stably deliver four ion species: C^6+, H^+, He^2+, and O^8+, and is equipped with multi-angle fixed treatment nozzles and a lightweight superconducting heavy-ion rotating gantry, integrating modulated scanning technology to advance the development and application of multi-ion combined therapy devices. On August 14, 2026, the device obtained an amendment to its Radiation Safety License from the Ministry of Ecology and Environment, granting qualification for commissioning and operation. In the early morning of August 20, the equipment achieved stable acceleration and precise extraction of carbon ion beams. Measured data show that the particle number after synchrotron acceleration reached 3.26E9 ppp, the terminal particle number reached 3.02E9 ppp, the extraction efficiency was 92%, and beam stability was no less than 95%.

2026-08-26

UK's InHealth Deploys Europe's First Mobile Biograph Trinion PET/CT System

InHealth, a UK independent diagnostic service provider, has recently completed the first patient scan using Europe's first mobile Biograph Trinion PET/CT system. The system, supplied by Siemens Healthineers, is now in clinical use at Wrexham Maelor Hospital in northeast Wales to support cancer-related molecular imaging examinations. PET/CT is an important imaging technology in oncology diagnosis and treatment, applicable to the diagnosis, staging, treatment planning, and therapy response monitoring of various cancer types. Deploying the Biograph Trinion PET/CT system on a mobile platform means that advanced molecular imaging services can be delivered into clinical settings with greater flexibility, helping to improve patient access to...

2026-08-26

Korea's Gil Medical Center Expands Application of Markerless Surface-Guided Radiation Therapy

Gachon University Gil Medical Center in South Korea announced on August 26 that it is expanding the clinical application of markerless surface-guided radiation therapy (SGRT) to enhance the precision and comfort of radiation therapy for cancer patients. According to the hospital, the proportion of markerless SGRT in its radiation therapy procedures has increased from 28% in the first half of 2025 to 37% in the first half of 2026. This change indicates that this treatment-assistive technology, which reduces the burden of skin marking on patients, is gaining broader clinical adoption. Markerless SGRT is an advanced technique used for patient positioning and monitoring during radiation therapy. Unlike conventional methods, patients do not need to retain target line markings on their skin; the treatment system can assist in confirming patient positioning through surface guidance, enabling radiation to be delivered more accurately to the target area.

2026-08-26

South Korean lawmaker calls for heavy ion therapy center in Daejeon to ease regional cancer treatment disparities

South Korean lawmaker Park Yong-gap recently called on the government to support the construction of a heavy ion therapy center in the central region of Daejeon, aiming to improve access to advanced radiation therapy for cancer patients outside the capital area and promote a balanced distribution of regional medical resources. Park stated that heavy ion therapy centers are often referred to as "dream cancer treatment centers." Compared with conventional radiation therapy, heavy ion therapy and proton therapy can target cancer cells more precisely while minimizing impact on surrounding normal tissues, making them advanced particle therapy technologies drawing attention in the current cancer treatment field. According to him, the relevant treatment centers currently in operation in South Korea are mainly concentrated in the capital area, including the heavy ion therapy center at Sinchon Severance Hospital of Yonsei University...

2026-08-26

Two production lines at radiopharmaceutical plant in Russia's Kaluga Region enter trial production

Rosatom recently announced that two production lines at its modern radiopharmaceutical manufacturing facility in the Kaluga Region have entered trial production. The facility, built in accordance with the Eurasian Economic Union's international Good Manufacturing Practice (GMP) standards, is equipped with high-level production equipment and is designed to supply safe, quality-controlled radiopharmaceuticals to the market. According to reports, Rosatom's subsidiary enterprises currently produce more than ten registered diagnostic and therapeutic radiopharmaceuticals, involving isotopes such as iodine-123, iodine-131, technetium-99m, and samarium-153. The new plant's production plan is based on the demand for radioisotope products from Russian medical institutions through 2030. The company...

2026-08-26